Connecting the Dots with Newer, Personalized Approaches for CLL
Much of the excitement at ASH 2011 for CLL has revolved around newer tools such as kinase inhibitors and chimeric antigen receptors. But that's not the whole story. Dr. Stephan Stilgenbauer, deputy director of the department of haematology at the University of Ulm in Germany, explains that researchers have made recent breakthroughs in their understanding of the disease itself. He describes data published at ASH 2011 that has given physicians insight into newly discovered genetic mutations. He states that the challenge for researchers in the future will be to compare these newer disease subtypes and identify which of the newer treatment approaches will give patients the best results.
Experts & Guests
Stephan Stilgenbauer, M.D.
Associate Professor at the Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of UlmDr. Stephan Stilgenbauer is Associate Professor in the Department of Hematology, Oncology, Rheumatology and Infectious Diseases at the University of Ulm, Germany. He received his medical training at Ruprecht-Karls Universität Heidelberg Medical School, Germany with electives in Hamilton, Canada; Jerusalem, Israel; Bath, UK and Cambridge, UK. He went on to complete his final year at the Baylor College of Medicine... more >